Streptococcus Pneumoniae Clinical Trial
Official title:
Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream
Streptococcus pneumoniae is a gram-positive (GP) bacteria responsible for common infections such as community-acquired pneumonia (CAP), as well as complicated infections such as bacteremia, infective endocarditis and meningitis. S. pneumoniae bacteremia ranks among the top 10 most common pathogens associated with bloodstream infections and correlates with high morbidity and mortality worldwide.
The Infectious Diseases Society of America (IDSA) guidelines for CAP management advocate for short courses of antibiotics for CAP treatment. However, it does not address duration of therapy for common CAP pathogens such as S. pneumoniae when associated with blood stream infections (BSI). 3 Currently, GP bacteremia duration of therapy typically ranges from 7 to 14 days based on IDSA guideline recommendations for Staphylococcus aureus bacteremia with no further definitive consensus.4 Additionally, lack of data and randomized clinical trials on the efficacy and safety of short compared to long treatment duration have led to variability in practice. Most randomized clinical trials as well as retrospective studies on treatment duration, have been conducted mainly in gram-negative BSI ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
| Completed |
NCT02215863 -
Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years
|
Phase 4 | |
| Completed |
NCT01521897 -
Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan)
|
N/A | |
| Completed |
NCT00197769 -
Immunogenicity of a Reduced Primary Schedule for Pneumococcal Conjugate Vaccine in UK Infants
|
Phase 2 | |
| Completed |
NCT02888457 -
Carriage of Streptococcus Pneumoniae in Infants With Acute Otitis Media and in Infants Attending Day-care Centers
|
N/A | |
| Completed |
NCT01995617 -
Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine
|
Phase 1 | |
| Completed |
NCT01425372 -
Evaluating Vaccine Responses in Healthy Infants Receiving Their Routine Primary Immunisation According to the Accelerated United Kingdom Schedule at 2, 3 and 4 Months
|
||
| Completed |
NCT00594347 -
Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar
|
Phase 3 | |
| Completed |
NCT00861380 -
Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease
|
Phase 3 | |
| Active, not recruiting |
NCT00900978 -
Impact of the 7 Valent Pneumococcal Conjugate Vaccine (7vPCV) on Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Jordanian Infants
|
Phase 1/Phase 2 | |
| Completed |
NCT00814710 -
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age
|
Phase 3 | |
| Suspended |
NCT01308827 -
Costa Rica Epidemiological Study on S. Pneumoniae
|
N/A | |
| Recruiting |
NCT04078997 -
An Evaluation of PCV13 Vaccine Schedules, Comparing Impact of 2+1 vs 3+0 on Pneumococcal Carriage in Blantyre, Malawi
|
||
| Terminated |
NCT00849069 -
Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine
|
Phase 1 | |
| Completed |
NCT00907777 -
Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™
|
Phase 3 | |
| Completed |
NCT00273325 -
Immunogenicity of PCV-7 Vaccine in VLBW Infants
|
||
| Completed |
NCT00814489 -
Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults
|
Phase 1 | |
| Completed |
NCT01730391 -
Neisseria Meningitidis Burden of Disease Study
|
N/A | |
| Completed |
NCT00197821 -
Evaluation of the Immunogenicity and Reactogenicity of a Pneumococcal Conjugate Vaccine in Healthy Adults
|
Phase 2 | |
| Completed |
NCT00839254 -
Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A
|
Phase 3 |